Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia ; volume:6 ; number:1 ; day:14 ; month:4 ; year:2017 ; pages:1-7 ; date:12.2017
Experimental hematology & oncology ; 6, Heft 1 (14.4.2017), 1-7, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Wei, Guoqing
- Contributor
-
Ding, Lijuan
Wang, Jiasheng
Hu, Yongxian
Huang, He
SpringerLink (Online service)
- DOI
-
10.1186/s40164-017-0070-9
- URN
-
urn:nbn:de:1111-201704309213
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wei, Guoqing
- Ding, Lijuan
- Wang, Jiasheng
- Hu, Yongxian
- Huang, He
- SpringerLink (Online service)
Other Objects (12)
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T‐cell therapy
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
Engineering better chimeric antigen receptor T cells
Special issue: CAR‐T cell therapy for hematological malignancies
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
An in vivo study of the best light emitting diode (LED) systems for cut chrysanthemums
Mesenchymal stem cells in rabbit meniscus and bone marrow exhibit a similar feature but a heterogeneous multi-differentiation potential: superiority of meniscus as a cell source for meniscus repair
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T‐cell therapy
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
Engineering better chimeric antigen receptor T cells
Special issue: CAR‐T cell therapy for hematological malignancies
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
An in vivo study of the best light emitting diode (LED) systems for cut chrysanthemums
Mesenchymal stem cells in rabbit meniscus and bone marrow exhibit a similar feature but a heterogeneous multi-differentiation potential: superiority of meniscus as a cell source for meniscus repair
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T‐cell therapy
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
Engineering better chimeric antigen receptor T cells
Special issue: CAR‐T cell therapy for hematological malignancies
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
An in vivo study of the best light emitting diode (LED) systems for cut chrysanthemums